Key takeaways
Lebrikizumab (Ebglyss) and dupilumab (Dupixent) are both injectable medications used to treat moderate-to-severe eczema. Both medications work by blocking proteins that play a role in causing inflammation. However, they have some important differences. Lebrikizumab is specifically approved for eczema in people 12 years and older, whereas dupilumab is approved for a broader range of conditions, including asthma, sinus congestion with nasal polyps, eosinophilic esophagitis, and prurigo nodularis, and can be used in children as young as 6 months for eczema. Lebrikizumab is injected every 4 weeks for maintenance, while dupilumab can be injected every 1 to 4 weeks, depending on the condition. Common side effects of lebrikizumab include pink eye and injection site reactions, whereas dupilumab may cause eye inflammation and joint pain. Both medications require caution with live vaccines due to potential interactions.
